Abeona Therapeutics (NASDAQ:ABEO) Director Eric Crombez Sells 26,143 Shares

Abeona Therapeutics Inc. (NASDAQ:ABEO) Director Eric Crombez sold 26,143 shares of Abeona Therapeutics stock in a transaction that occurred on Friday, May 15th. The shares were sold at an average price of $5.53, for a total transaction of $144,570.79. Following the completion of the transaction, the director directly owned 37,313 shares in the company, valued at approximately $206,340.89. The trade was a 41.20% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Abeona Therapeutics Stock Down 2.0%

ABEO traded down $0.11 during trading on Friday, reaching $5.49. The company had a trading volume of 1,515,848 shares, compared to its average volume of 1,218,036. The company has a debt-to-equity ratio of 0.05, a current ratio of 6.93 and a quick ratio of 6.74. Abeona Therapeutics Inc. has a 12 month low of $4.00 and a 12 month high of $7.54. The business’s fifty day moving average price is $5.08 and its 200 day moving average price is $5.04. The company has a market cap of $312.27 million, a P/E ratio of 5.66 and a beta of 1.35.

Abeona Therapeutics (NASDAQ:ABEO) last announced its quarterly earnings results on Wednesday, May 13th. The biopharmaceutical company reported ($0.30) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.03. The company had revenue of $8.72 million during the quarter, compared to the consensus estimate of $4.57 million. Equities analysts anticipate that Abeona Therapeutics Inc. will post -0.73 EPS for the current year.

Analysts Set New Price Targets

ABEO has been the topic of a number of research reports. Oppenheimer reaffirmed an “outperform” rating on shares of Abeona Therapeutics in a research note on Monday, March 9th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Abeona Therapeutics in a research note on Wednesday, January 21st. Stifel Nicolaus set a $17.00 price target on shares of Abeona Therapeutics in a research note on Tuesday, March 17th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $20.00 price target on shares of Abeona Therapeutics in a research note on Thursday, March 19th. Three investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $19.00.

Institutional Trading of Abeona Therapeutics

Institutional investors have recently made changes to their positions in the business. Legal & General Group Plc bought a new stake in shares of Abeona Therapeutics in the second quarter worth $27,000. Russell Investments Group Ltd. bought a new stake in shares of Abeona Therapeutics in the third quarter worth $37,000. Truvestments Capital LLC lifted its position in shares of Abeona Therapeutics by 191.4% in the fourth quarter. Truvestments Capital LLC now owns 10,307 shares of the biopharmaceutical company’s stock worth $54,000 after purchasing an additional 6,770 shares in the last quarter. SG Americas Securities LLC bought a new stake in shares of Abeona Therapeutics in the fourth quarter worth $57,000. Finally, Legato Capital Management LLC bought a new stake in shares of Abeona Therapeutics in the third quarter worth $57,000. Institutional investors own 80.56% of the company’s stock.

About Abeona Therapeutics

Abeona Therapeutics is a clinical‐stage biopharmaceutical company focused on the development and commercialization of gene and cell therapies for severe, life‐threatening rare diseases and oncology indications. Founded in 2014 and headquartered in Cleveland, Ohio, Abeona leverages proprietary viral and non‐viral delivery platforms to correct or compensate for underlying genetic deficiencies. The company’s research efforts target pediatric neurodegenerative disorders as well as debilitating dermatologic conditions with high unmet medical need.

The company’s lead clinical programs include separate AAV‐based gene therapies for CLN1 and CLN3 forms of neuronal ceroid lipofuscinosis, alongside an ex vivo autologous cell therapy for recessive dystrophic epidermolysis bullosa.